Skip to content
Screener

Sionna Therapeutics SION Return on equity

Return on equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
23.5%—
AbbVie logo
AbbVieABBV
89%+32.7pp
Achieve Life Sciences logo
Achieve Life SciencesACHV
-496.1%-906pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-6.3%—
RFL
Rafael Holdings, Inc.RFL
-26.6%-0.8pp
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-45.4%+29.8pp

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$203.46M-77.0%
Enterprise value$147.55M-82.7%

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio22.6×-6.1×

Where this comes from

Calculated from Sionna Therapeutics’s reported figures.

net income/total stockholders equity=-26.7%

Based on trailing twelve months.

The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 7:17 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033876

FAQ

What is Sionna Therapeutics's return on equity?
Sionna Therapeutics (SION) reported return on equity of -26.7% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Sionna Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude